Breaking News, Financial News

Financial Report: Emergent BioSolutions

Cangene ops boost revenue in the quarter

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergent BioSolutions

2Q Revenues: $110.3 million (+34%)

2Q Earnings: $5.0 million (+51%)

YTD Revenues: $164.2 million (+31%)

YTD Loss: $15.2 million (earnings were $2.4 million YTD13)

Comments: This was the first full quarter of combined operations with Cangene.Product sales were $78.3 million, up 19%. Revenue from BioThrax was $67.5 million in the quarter, up 3%. Contract manufacturing revenue was $9.2 million in the quarter. R&D expenses were $37.4 million, up 23% primarily due to higher contract service costs, and includes increased technology and development expenses in both the Biodefense and Biosciences divisions.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters